Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G U Corsini

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
Brain Research|February 7, 1992
Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranesM Del Zompo, M P Piccardi, S Ruiu, et al.
Brain Research|July 23, 1986
Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: binding and biochemical studiesM Del Zompo, M P Piccardi, F Bernardi, et al.
Journal of Neurochemistry|April 1, 1996
Identification and determination of 3,4-dihydroxyphenylacetaldehyde, the dopamine metabolite in in vivo dialysate from rat striatumA Colzi, A Musolino, A Iuliano, et al.
Journal of Neural Transmission. Supplementum|January 1, 1986
Primate-rodent 3H-MPTP binding differences, and biotransformation of MPTP to a reactive intermediate in vitroG U Corsini, S Pintus, A Bocchetta, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1986
A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidaseG U Corsini, S Pintus, A Bocchetta, et al.
Journal of Neurochemistry|September 1, 1985
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitroA Bocchetta, M P Piccardi, M Del Zompo, et al.
Journal of Neurochemistry|February 4, 1999
Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine lossesF Fornai, F S Giorgi, M G Alessandrì, et al.
Psychopharmacology|October 31, 1978
Parkinsonism by haloperidol and piribedilG U Corsini, M Del Zompo, A Spissu, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 1997
Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletionsF Fornai, M G Alessandrì, M T Torracca, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 22, 1999
G protein-linked receptors: pharmacological evidence for the formation of heterodimersR Maggio, P Barbier, A Colelli, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Brain Research|February 7, 1992
Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranesM Del Zompo, M P Piccardi, S Ruiu, et al.
Brain Research|July 23, 1986
Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: binding and biochemical studiesM Del Zompo, M P Piccardi, F Bernardi, et al.
Journal of Neurochemistry|April 1, 1996
Identification and determination of 3,4-dihydroxyphenylacetaldehyde, the dopamine metabolite in in vivo dialysate from rat striatumA Colzi, A Musolino, A Iuliano, et al.
Journal of Neural Transmission. Supplementum|January 1, 1986
Primate-rodent 3H-MPTP binding differences, and biotransformation of MPTP to a reactive intermediate in vitroG U Corsini, S Pintus, A Bocchetta, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1986
A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidaseG U Corsini, S Pintus, A Bocchetta, et al.
Journal of Neurochemistry|September 1, 1985
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitroA Bocchetta, M P Piccardi, M Del Zompo, et al.
Journal of Neurochemistry|February 4, 1999
Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine lossesF Fornai, F S Giorgi, M G Alessandrì, et al.
Psychopharmacology|October 31, 1978
Parkinsonism by haloperidol and piribedilG U Corsini, M Del Zompo, A Spissu, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 1997
Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletionsF Fornai, M G Alessandrì, M T Torracca, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 22, 1999
G protein-linked receptors: pharmacological evidence for the formation of heterodimersR Maggio, P Barbier, A Colelli, et al.
Pageof 8